Background::The calcineurin inhibitor (CNI)-based immune maintenance regimen that is commonly used after renal transplantation has greatly improved early graft survival after transplantation; however, the long-term prognosis of grafts has not been significantly improved. The nephrotoxicity of CNI drugs is one of the main risk factors for the poor long-term prognosis of grafts. Sirolimus (SRL) has been employed as an immunosuppressant in clinical practice for over 20 years and has been found to have no nephrotoxic effects on grafts. Presently, the regimen and timing of SRL application after renal transplantation vary, and clinical data are scarce. Multicenter prospective randomized controlled studies are particularly rare. This study aims to investigate the effects of early conversion to a low-dose CNI combined with SRL on the long-term prognosis of renal transplantation.Methods::Patients who receive four weeks of a standard regimen with CNI + mycophenolic acid (MPA) + glucocorticoid after renal transplantatio

作者：Zheng Xiang；Zhang Weijie；Zhou Hua；Cao Ronghua；Shou Zhangfei；Zhang Shuwei；Cheng Ying；Chen Xuchun；Ding Chenguang；Tang Zuofu；Li Ning；Shi Shaohua；Zhou Qiang；Chen Qiuyuan；Chen Gang；Chen Zheng；Zhou Peijun；Hu Xiaopeng；Zhang Xiaodong；Na Ning；Wang Wei

来源：中华医学杂志英文版 2022 年 135卷 13期